Atara Biotherapeutics Stock Investor Sentiment
| ATRA Stock | USD 7.49 0.35 4.90% |
About 57% of all Atara Biotherapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Atara Biotherapeutics suggests that some traders are interested. The current market sentiment, together with Atara Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Atara Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Atara Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Atara Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Atara Biotherapeutics' Stock prices. Below is the latest headlines and news related to Atara Biotherapeutics Stock. The global stock market is bullish. About 68% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Atara Biotherapeutics that are available to investors today. This information is accessible both publicly - through Atara Biotherapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Atara-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Atara Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Atara Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Atara Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Atara Biotherapeutics alpha.
Atara Largest EPS Surprises
Earnings surprises can significantly impact Atara Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2024-03-28 | 2023-12-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2022-05-05 | 2022-03-31 | -0.98 | -0.87 | 0.11 | 11 | ||
2016-11-04 | 2016-09-30 | -0.77 | -0.88 | -0.11 | 14 | ||
2018-05-08 | 2018-03-31 | -0.92 | -1.05 | -0.13 | 14 | ||
2015-11-05 | 2015-09-30 | -0.56 | -0.43 | 0.13 | 23 |
There is far too much social signal, news, headlines, and media speculation about Atara Biotherapeutics that are available to investors today. This information is accessible both publicly - through Atara Biotherapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Atara-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Atara Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Atara Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Atara Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Atara Biotherapeutics alpha.
Atara Biotherapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Atara Biotherapeutics Moves to Buy Rationale Behind the Upgrade | 03/13/2025 |
2 | Disposition of 77108 shares by Anhco Nguyen of Atara Biotherapeutics at 10.21 subject to Rule 16b-3 | 04/28/2025 |
3 | Atara Biotherapeutics Provides Regulatory Updates on EBVALLO | 05/05/2025 |
4 | Atara Biotherapeutics to reduce workforce by 30 | 05/12/2025 |
5 | Atara Biotherapeutics Announces Pricing of 16Million Offering | 05/15/2025 |
6 | Atara Biotherapeutics First Quarter 2025 Earnings Beats Expectations | 05/16/2025 |
7 | Atara Biotherapeutics, Inc. CAO Sells 14,993.68 in Stock | 05/23/2025 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |